The DOI matches its Crossref record; 236 of the 236 references it cites were found in a registry or an index.
Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit
Abstract
Kit is a receptor tyrosine kinase (RTK) that binds stem cell factor. This receptor ligand combination is important for normal hematopoiesis, as well as pigmentation, gut function, and reproduction. Structurally, Kit has both an extracellular and intracellular region. Theintra-cellular region is comprised of a juxtamembrane domain (JMD), a kinase domain, a kinase insert, and a carboxyl tail. Inappropriate expression or activation of Kit is associated with a variety of diseases in humans. Activating mutations in Kit have been identified primarily in the JMD and the second part of the kinase domain and have been associated with gastrointestinal stromal cell tumors and mastocytosis, respectively. There are also reports of activating mutations in some forms of germ cell tumors and core binding factor leukemias. Since the cloning of the Kit ligand in the early 1990s, there has been an explosion of information relating to the mechanism of action of normal forms of Kit as well as activated mutants. This is important because understanding this RTK at the biochemical level could assist in the development of therapeutics to treat primary and secondary defects in the tissues that require Kit. Furthermore, understanding the mechanisms mediating transformation of cells by activated Kit mutants will help in the design of interventions for human disease associated with these mutations. The objective of this review is to summarize what is known about normal and oncogenic forms of Kit. We will place particular emphasis on recent developments in understanding the mechanisms of action of normal and activated forms of this RTK and its association with human disease, particularly in hematopoietic cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–236 of 236
Effects of Mutant c-Kit in Early Myeloid Cells
Ashman, L. K., Ferrao, P., Cole, S. R., & Cambareri, A. C. (1999) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199909058472 · Cited by 52
Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients
Weisberg, E., & Griffin, J. D. (2001) · Drug Resistance Updates · doi:10.1054/drup.2001.0180 · Cited by 51
Evidence that juvenile myelomonocytic leukemia can arise from a pluripotential stem cell
Cooper, L. J. N., Shannon, K., Loken, M. R., Weaver, M., Stephens, K. G., & Sievers, E. L. (2000) · Blood · doi:10.1182/blood.v96.6.2310 · Cited by 50
Embryonic Beginnings of Definitive Hematopoietic Stem Cells
Dzierzak, E. A. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb08470.x · Cited by 49
Lennartsson, J., Wernstedt, C., Engström, U., Hellman, U., & Rönnstrand, L. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(03)00206-4 · Cited by 48
Self-citationExpression, Function and Activation of the Proto-oncogenec-kitProduct in Human Leukemia Cells
Kanakura, Y., Ikeda, H., Kitayama, H., Sugahara, H., & Furitsu, T. (1993) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199309147354 · Cited by 46
c-Kit Point mutation in patients with myeloproliferative disorders
Kimura, A., Nakata, Y., Katoh, O., & Hyodo, H. (1997) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199709114167 · Cited by 46
FLT3 and its Role in the Pathogenesis of Acute Myeloid Leukaemia
Reilly, J. T. (2002) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819021000040233 · Cited by 45
Kozawa, O., Blume‐Jensen, P., Heldin, C., & Rönnstrand, L. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00149.x · Cited by 45
Integrative Signaling by Minimal Erythropoietin Receptor Forms and c-Kit
Pircher, T. J., Geiger, J. N., Zhang, D., Miller, C. P., Gaines, P. C. W., & Wojchowski, D. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007473200 · Cited by 45
Koike, T., Hirai, K., Morita, Y., & Nozawa, Y. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.1.359 · Cited by 44
Zhao, S., Zoller, K., Masuko, M., Rojnuckarin, P., Yang, X. O., Parganas, E., Kaushansky, K., Ihle, J. N., Papayannopoulou, T., Willerford, D. M., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/21.9.2159 · Cited by 44
Hallek, M. J., Druker, B. J., Lepisto, E. M., Wood, K. W., Ernst, T. J., & Griffin, J. D. (1992) · Journal of Cellular Physiology · doi:10.1002/jcp.1041530122 · Cited by 43
Bondzi, C., Litz, J., Dent, P., & Krystal, G. W. (2000) · PubMed · Cited by 43
Ratajczak, M. Z., Kuczyński, W. I., Sokol, D. L., Moore, J., Pletcher, C. H., & Gewirtz, A. (1995) · Blood · doi:10.1182/blood.v86.6.2161.bloodjournal8662161 · Cited by 39
Inhibition of c-kit ligand/steel factor by antibodies reduces survival of lethally irradiated mice
Neta, R., Williams, D., Selzer, F., et al. (1993) · Blood · doi:10.1182/blood.v81.2.324.324 · Cited by 39
Herbst, R., Shearman, M. S., Jallal, B., Schlessinger, J., & Ullrich, A. (1995) · Biochemistry · doi:10.1021/bi00017a026 · Cited by 37
c-kit expression in human megakaryoblastic leukemia cell lines
Hu, Z., Ma, W., Uphoff, C., Quentmeier, H., & Drexler, H. G. (1994) · Blood · doi:10.1182/blood.v83.8.2133.2133 · Cited by 37
c-kit ligand stimulates tyrosine phosphorylation of the c-Cbl protein in human hematopoietic cells.
Wisniewski, D. J., Strife, A., & Clarkson, B. (1996) · PubMed · Cited by 36
Goff, J. P., Shields, D. S., Petersen, B. E., Zajac, V. F., Michalopoulos, G. K., & Greenberger, J. S. (1996) · Stem Cells · doi:10.1002/stem.140592 · Cited by 33
Radošević, N., Winterstein, D., Keller, J. R., Neubauer, H. J., Pfeffer, K., & Linnekin, D. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2003.11.006 · Cited by 33
Self-citationJAK2 Is Constitutively Associated with c-Kit and Is Phosphorylated in Response to Stem Cell Factor
Linnekin, D., Weiler, S. R., Mou, S. M., DeBerry, C. S., Keller, J. R., Ruscetti, F. W., Ferris, D. K., & Longo, D. L. (2009) · Acta Haematologica · doi:10.1159/000203882 · Cited by 33
Self-citationTan, B. L., Hong, L., Munugalavadla, V., & Kapur, R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207068200 · Cited by 32
High expression of both mutant and wild-type alleles of c-kit in gastrointestinal stromal tumors
Théou–Anton, N., Tabone‐Eglinger, S., Saffroy, R., Cesne, A. L., Julié, C., Cortez, A., Lavergne‐Slove, A., Debuire, B., Lemoine, A., & Emile, J. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2003.12.011 · Cited by 31
Discorde, M. L., Prost, S., Nandrot, E. F., & Kirszenbaum, M. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01725.x · Cited by 30
Miller, C. P., Liu, Z. Y., Noguchi, C. T., & Wojchowski, D. M. (1999) · Blood · doi:10.1182/blood.v94.10.3381.422k25_3381_3387 · Cited by 30
Paner, G. P., Silberman, S., Hartman, G., Micetich, K. C., Aranha, G. V., & Alkan, S. (2003) · PubMed · Cited by 28
Kit signaling and negative regulation of daunorubicin-induced apoptosis: role of phospholipase Cγ
Plo, I., Lautier, D., Castéran, N., Dubreuil, P. C., Arock, M., & Laurent, G. (2001) · Oncogene · doi:10.1038/sj.onc.1204877 · Cited by 23
Boer, A., Drayer, A. L., & Vellenga, E. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00075-4 · Cited by 21
Frostad, S., Bjerknes, R., Abrahamsen, J. F., Olweus, J., & Bruserud, Ø. (1998) · Stem Cells · doi:10.1002/stem.160334 · Cited by 21
Leslie, N. R., O’Prey, J., Bartholomew, C., & Harrison, P. R. (1998) · Blood · doi:10.1182/blood.v92.12.4798 · Cited by 21
Lee, Y., Mantel, C., Anzai, N., Braun, S. E., & Broxmeyer, H. E. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4215 · Cited by 20
Suppressor of Cytokine Signaling 1 Regulates an Endogenous Inhibitor of a Mast Cell Protease
Ilangumaran, S., Finan, D., Raine, J. C., & Rottapel, R. K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308382200 · Cited by 14
Kamijo, T., Koike, K., Takeuch, K., Higuchi, T., Sawai, N., Kikuchi, T., Tsumura, H., Akiyama, H., Koike, T., Ishii, E., et al. (1997) · Leukemia Research · doi:10.1016/s0145-2126(97)00086-6 · Cited by 11
Okubo, T., Yanai, N., Ikawa, S., & Obinata, M. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(02)00899-8 · Cited by 7
Reddy, G. P., & Quesenberry, P. (1996) · Blood · doi:10.1182/blood.v87.8.3195.bloodjournal8783195 · Cited by 5
Cited by
Stem Cell Factor Receptor/c-Kit: From Basic Science to Clinical Implications
Lennartsson, J., & Rönnstrand, L. (2012) · Physiological Reviews · doi:10.1152/physrev.00046.2011 · Cited by 825
Self-citationPaschka, P., Marcucci, G., Ruppert, A. S., Mrózek, K., Chen, H., Kittles, R. A., Vukosavljevic, T., Perrotti, D., Vardiman, J. W., Carroll, A. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.9500 · Cited by 663
NF-κB addiction and its role in cancer: ‘one size does not fit all’
Chaturvedi, M. M., Sung, B., Yadav, V. R., Kannappan, R., & Aggarwal, B. B. (2011) · Oncogene · doi:10.1038/onc.2010.566 · Cited by 473
The tyrosine kinase network regulating mast cell activation
Gilfillan, A. M., & Rivera, J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00742.x · Cited by 428
Development, Migration, and Survival of Mast Cells
Okayama, Y., & Kawakami, T. (2006) · Immunologic Research · doi:10.1385/ir:34:2:97 · Cited by 427
Metadata
- Authors
- Lennartsson, J., Jelacic, T., Linnekin, D., & Shivakrupa, R.
- Venue
- STEM CELLS
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-01
- Volume
- 23
- Issue
- 1
- Pages
- 16-43
- ISSN
- 1066-5099 (ISSN-L)
- 1549-4918
- OpenAlex
- W2053690380
- Cited by
- 303
- References
- 236
- FWCI
- 7.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.